IceCure Medical announces data presented at Japanese Breast Cancer Society event

IceCure Medical (ICCM) announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society’s Conference, which took place earlier this month in Tokyo. On Friday, July 11, Professor Eisuke Fukuma, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma’s presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated; The overall ipsilateral breast tumor recurrence rate was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate; For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. “We believe ProSense can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year’s Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants. Working with Terumo Corporation in Japan, the country’s largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies,” stated Eyal Shamir, IceCure’s Chief Executive Officer.